T. Rowe Price Associates’s HealthEquity HQY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $89.8M | Buy |
994,551
+191,124
| +24% | +$16.2M | 0.01% | 726 |
|
|
2026
Q1 | $67.1M | Sell |
803,427
-514,292
| -39% | -$42.2M | 0.01% | 705 |
|
|
2025
Q4 | $121M | Sell |
1,317,719
-216,011
| -14% | -$20.7M | 0.01% | 591 |
|
|
2025
Q3 | $145M | Buy |
1,533,730
+833,361
| +119% | +$78.4M | 0.02% | 529 |
|
|
2025
Q2 | $73.4M | Buy |
700,369
+61,024
| +10% | +$5.78M | 0.01% | 637 |
|
|
2025
Q1 | $56.5M | Buy |
639,345
+580,988
| +996% | +$59.6M | 0.01% | 691 |
|
|
2024
Q4 | $5.6M | Buy |
58,357
+4,263
| +8% | +$397K | ﹤0.01% | 1261 |
|
|
2024
Q3 | $4.43M | Sell |
54,094
-610
| -1% | -$47.1K | ﹤0.01% | 1328 |
|
|
2024
Q2 | $4.72M | Buy |
54,704
+3,320
| +6% | +$268K | ﹤0.01% | 1239 |
|
|
2024
Q1 | $4.2M | Buy |
51,384
+3,365
| +7% | +$263K | ﹤0.01% | 1263 |
|
|
2023
Q4 | $3.18M | Buy |
48,019
+2,712
| +6% | +$188K | ﹤0.01% | 1349 |
|
|
2023
Q3 | $3.31M | Buy |
45,307
+2,325
| +5% | +$157K | ﹤0.01% | 1295 |
|
|
2023
Q2 | $2.71M | Buy |
42,982
+1,598
| +4% | +$92.7K | ﹤0.01% | 1374 |
|
|
2023
Q1 | $2.43M | Sell |
41,384
-6,295
| -13% | -$382K | ﹤0.01% | 1404 |
|
|
2022
Q4 | $2.94M | Buy |
47,679
+2,188
| +5% | +$147K | ﹤0.01% | 1334 |
|
|
2022
Q3 | $3.06M | Sell |
45,491
-3,232
| -7% | -$205K | ﹤0.01% | 1297 |
|
|
2022
Q2 | $2.99M | Buy |
48,723
+4,111
| +9% | +$263K | ﹤0.01% | 1508 |
|
|
2022
Q1 | $3.01M | Buy |
44,612
+3,559
| +9% | +$192K | ﹤0.01% | 1568 |
|
|
2021
Q4 | $1.82M | Buy |
41,053
+5,129
| +14% | +$299K | ﹤0.01% | 1759 |
|
|
2021
Q3 | $2.33M | Sell |
35,924
-655
| -2% | -$45.5K | ﹤0.01% | 1669 |
|
|
2021
Q2 | $2.94M | Sell |
36,579
-4,031
| -10% | -$307K | ﹤0.01% | 1617 |
|
|
2021
Q1 | $2.76M | Buy |
40,610
+2,028
| +5% | +$159K | ﹤0.01% | 1607 |
|
|
2020
Q4 | $2.69M | Sell |
38,582
-285
| -0.7% | -$17.7K | ﹤0.01% | 1553 |
|
|
2020
Q3 | $2M | Buy |
38,867
+299
| +0.8% | +$16.4K | ﹤0.01% | 1552 |
|
|
2020
Q2 | $2.26M | Sell |
38,568
-10,291
| -21% | -$569K | ﹤0.01% | 1511 |
|
|
2020
Q1 | $2.47M | Sell |
48,859
-4,217
| -8% | -$280K | ﹤0.01% | 1456 |
|
|
2019
Q4 | $3.93M | Buy |
53,076
+2,741
| +5% | +$171K | ﹤0.01% | 1439 |
|
|
2019
Q3 | $2.88M | Buy |
50,335
+12,603
| +33% | +$836K | ﹤0.01% | 1484 |
|
|
2019
Q2 | $2.47M | Buy |
37,732
+259
| +0.7% | +$18K | ﹤0.01% | 1530 |
|
|
2019
Q1 | $2.77M | Buy |
37,473
+4,451
| +13% | +$313K | ﹤0.01% | 1504 |
|
|
2018
Q4 | $1.97M | Buy |
33,022
+125
| +0.4% | +$10.1K | ﹤0.01% | 1568 |
|
|
2018
Q3 | $3.11M | Buy |
32,897
+1,784
| +6% | +$154K | ﹤0.01% | 1521 |
|
|
2018
Q2 | $2.34M | Buy |
31,113
+986
| +3% | +$70.8K | ﹤0.01% | 1554 |
|
|
2018
Q1 | $1.82M | Buy |
30,127
+3,297
| +12% | +$179K | ﹤0.01% | 1601 |
|
|
2017
Q4 | $1.25M | Buy |
26,830
+4,490
| +20% | +$222K | ﹤0.01% | 1710 |
|
|
2017
Q3 | $1.13M | Buy |
22,340
+2,600
| +13% | +$121K | ﹤0.01% | 1767 |
|
|
2017
Q2 | $984K | Buy |
19,740
+21
| +0.1% | +$982 | ﹤0.01% | 1791 |
|
|
2017
Q1 | $837K | Buy |
19,719
+10,000
| +103% | +$443K | ﹤0.01% | 1858 |
|
|
2016
Q4 | $394K | Sell |
9,719
-16
| -0.2% | -$618 | ﹤0.01% | 2151 |
|
|
2016
Q3 | $368K | Hold |
9,735
| – | – | ﹤0.01% | 2133 |
|
|
2016
Q2 | $296K | Sell |
9,735
-136,275
| -93% | -$3.58M | ﹤0.01% | 2175 |
|
|
2016
Q1 | $3.6M | Sell |
146,010
-7,470
| -5% | -$160K | ﹤0.01% | 1437 |
|
|
2015
Q4 | $3.85M | Buy |
153,480
+6,790
| +5% | +$209K | ﹤0.01% | 1457 |
|
|
2015
Q3 | $4.33M | Buy |
146,690
+3,600
| +3% | +$113K | ﹤0.01% | 1454 |
|
|
2015
Q2 | $4.59M | Sell |
143,090
-100
| -0.1% | -$2.69K | ﹤0.01% | 1497 |
|
|
2015
Q1 | $3.58M | Buy |
143,190
+2,790
| +2% | +$60.5K | ﹤0.01% | 1514 |
|
|
2014
Q4 | $3.57M | Buy |
140,400
+1,600
| +1% | +$34.7K | ﹤0.01% | 1505 |
|
|
2014
Q3 | $2.54M | Buy |
+138,800
| New | +$2.66M | ﹤0.01% | 1544 |
|
Other funds holding HQY
WA
T. Rowe Price Associates's HQY Position: Q2 2026 in Review
T. Rowe Price Associates increased its HealthEquity (HQY) stake by 24% in Q2 2026, buying an estimated $16.2M and bringing the position to 994,551 shares worth $89.8M. The position accounts for 0.01% of the portfolio, ranked #726.
T. Rowe Price Associates first reported a position in HQY in Q3 2014 and has held it in 48 quarters since. The position peaked at $145M in Q3 2025. 498 funds tracked by Wall St. Rank hold HQY as of Q2 2026.
- T. Rowe Price Associates held 994,551 shares of HealthEquity worth $89.8M as of Q2 2026.
- T. Rowe Price Associates bought 191,124 HealthEquity shares in Q2 2026, an estimated $16.2M.
- HealthEquity made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #726 holding.
- T. Rowe Price Associates first reported a position in HealthEquity in Q3 2014 and has held it in 48 quarters since.
- T. Rowe Price Associates's HealthEquity position peaked at $145M in Q3 2025.
- 498 funds tracked by Wall St. Rank held HealthEquity as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.